查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球动物用药品市场（至2031年）：依产品（药品、单株抗体、免疫调节剂、药用饲料添加剂）、给药途径、剂型、适应症、动物分类（伴侣动物、家畜）、分销管道及最终用户划分
市场调查报告书
商品编码
1996977

全球动物用药品市场（至2031年）：依产品（药品、单株抗体、免疫调节剂、药用饲料添加剂）、给药途径、剂型、适应症、动物分类（伴侣动物、家畜）、分销管道及最终用户划分

Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User-Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 483 Pages | 订单完成后即时交付

价格

预计从 2026 年到 2031 年，全球动物用药品市场规模将以 6.3% 的复合年增长率成长。

这反映出宠物和牲畜市场均呈现稳定成长态势。

调查范围
调查期 2023-2031
基准年 2025
预测期 2026-2031
单元 金额（美元），数量（单位）
部分 依产品类型、给药途径、剂型、适应症、动物种类、通路和最终用户进行分类。
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

该市场的成长主要受宠物「人性化」趋势、慢性疾病和感染疾病的日益普遍以及对先进治疗方法投入的增加所驱动。在畜牧业，提高生产力的压力和更严格的食品安全标准持续推动对药品的需求，市场也保持着5%左右的低成长率。

兽药市场-IMG1

“按产品类型划分，预计单株抗体领域在预测期内将呈现最高的成长率。”

单株抗体领域预计将成为成长最快的领域，这主要得益于人们对标靶性、长效治疗方法的日益青睐，尤其是在伴侣动物领域。慢性疾病（如异位性皮肤炎、骨关节炎和免疫介导性疾病）负担的加重也推动了市场需求。这些治疗方法具有作用精准、副作用少、给药间隔长等优势，有助于提高病患的依从性。此外，生物製药研发的持续投入以及高端宠物护理市场的不断扩张，也进一步推动了该领域的成长。

“根据相关数据，预计到 2025 年，皮肤病领域将占据最大的市场份额。”

这主要是由于伴侣动物和家畜普遍存在皮肤疾病。常见的皮肤病，例如异位性皮肤炎、寄生虫感染疾病、真菌感染和细菌性皮肤感染疾病，都需要持续的治疗和药物。宠物数量的增加、人们对动物卫生日益增长的关注，以及对驱虫药、抗真菌药物和抗炎药物的强劲需求，进一步巩固了这一领域的市场主导地位。

“北美将在2025年引领市场”

北美预计将在2025年引领市场，这得益于其成熟的动物医疗保健生态系统和强大的购买力。该地区伴侣动物的治疗成本高昂，并拥有大规模的商业畜牧业基础。积极的研发投入、创新药物的快速核准流程以及主要生产商的强大实力进一步巩固了其市场地位。完善的分销网络和日益增强的动物预防保健意识也为该地区的主导市场地位做出了贡献。

本报告考察了全球动物用药品市场，提供了市场概述、影响市场成长的各种因素分析、技术和专利趋势、法律制度、案例研究、市场规模趋势和预测、按各个细分市场和地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

第一章：引言

第二章执行摘要

第三章重要考察

第四章 市场概览

  • 市场动态
    • 促进因素
    • 抑制因子
    • 机会
    • 任务
  • 未满足的需求和閒置频段
  • 与相关市场和不同产业相关的跨领域机会
  • 一、二、三级企业的策略性倡议

第五章 产业趋势

  • 波特五力分析
  • 总体经济指标
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 价格分析
  • 贸易分析
  • 2026-2027 年主要会议和活动
  • 影响客户业务的趋势/颠覆性因素
  • 投资和资金筹措场景
  • 案例研究分析
  • 美国关税对2025年动物用药品市场的影响

第六章：技术进步、人工智慧的影响、专利、创新与未来应用

  • 技术分析
    • 主要新兴技术
    • 互补技术
    • 邻近技术
  • 技术/产品蓝图
  • 专利分析
  • 未来应用
    • 精准的牲畜健康管理
    • 肿瘤和慢性病管理
    • 提高牲畜的繁殖和生育能力
    • 综合疾病监测与疫情控制
  • 生成式人工智慧对动物用药品市场的影响

第七章：监理情势与永续性倡议

  • 当地法规和合规性
  • 对永续性的承诺
  • 认证、标籤检视、环境标准

第八章：顾客趋势与购买行为

  • 决策流程
  • 采购过程中的关键相关人员及其评估标准
  • 实施障碍和内部挑战
  • 各种终端使用者环境中未被满足的需求
  • 市场盈利

第九章：动物用药品市场：依产品类型划分

  • 药物
    • 抗生素
    • 抗真菌药物
    • 抗病毒药物
    • 抗发炎药
    • 抗寄生虫药物
    • 抗癌药物
    • 心血管和肾臟药物
    • 消化器官系统药物
    • 其他的
  • 单株抗体
  • 免疫调节剂
  • 药用饲料添加剂
    • 胺基酸
    • 酵素
    • 维生素和矿物质
    • 其他的

第十章：动物用药品市场：依给药途径划分

  • 口服
  • 肠外
  • 局部的
  • 其他的

第十一章动物用药品市场：依剂型分类

  • 固态的
  • 液体
  • 半固态
  • 气雾剂/喷雾
  • 预混合料

第十二章动物用药品市场：依适应症划分

  • 感染疾病
  • 皮肤病
  • 疼痛管理
  • 心血管疾病和肾臟疾病
  • 消化系统疾病
  • 其他的

第十三章：动物用药品市场：依动物类型划分

  • 伴侣动物
    • 狗
    • 猫
    • 马
    • 其他的
  • 家畜
    • 牛
    • 猪
    • 家禽
    • 其他的

第十四章动物用药品市场：依通路划分

  • 兽药
  • 零售药房
  • 网路药房
  • 直销

第十五章：动物用药品市场：依最终用户划分

  • 动物医院和动物诊所
  • 畜牧场
  • 居家护理设施
  • 其他的

第十六章：动物用药品市场：依地区划分

  • 北美洲
    • 宏观经济展望
    • 市场规模分析与预测
    • 我们
    • 加拿大
  • 欧洲
    • 宏观经济展望
    • 市场规模分析与预测
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 宏观经济展望
    • 市场规模分析与预测
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 菲律宾
    • 其他的
  • 拉丁美洲
    • 宏观经济展望
    • 市场规模分析与预测
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲
    • 宏观经济展望
    • 市场规模分析与预测
  • 海湾合作委员会国家
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他海湾合作委员会国家
    • 其他中东和非洲地区

第十七章 竞争格局

    • 主要企业/主要企业的竞争策略
    • 美国：动物用药品市场份额分析
    • 欧洲：动物用药品市场份额分析
  • 产品/品牌对比
  • 企业估值矩阵：主要企业
  • 公司估值矩阵：Start-Ups/中小企业
  • 企业估值和财务指标
  • 竞争格局

第十八章：公司简介

  • 主要企业
    • ZOETIS INC.
    • MERCK & CO., INC
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • ELANCO ANIMAL HEALTH INCORPORATED
    • VIRBAC
    • CEVA
    • VETOQUINOL
    • DECHRA PHARMACEUTICALS PLC
    • NORBROOK
    • BIMEDA CORPORATE
    • HESTER BIOSCIENCES LIMITED
    • INDIAN IMMUNOLOGICALS LTD.
    • ANIMALCARE GROUP PLC
    • KYORITSU SEIYAKU CORPORATION
    • CALIER
  • 其他公司
    • DOPHARMA
    • PHARMGATE ANIMAL HEALTH
    • BIOVETA, AS
    • NEXTMUNE
    • TRIVIUMVET
    • DOMES PHARMA
    • UNIVET LIMITED
    • CENAVISA, SL
    • FATRO SPA
    • CHANELLE PHARMA

第十九章：调查方法

第20章附录

Product Code: PH 10279

The global veterinary pharmaceuticals market is projected to grow at a CAGR of 6.3% from 2026 to 2031, reflecting steady expansion across both companion and livestock segments.

Scope of the Report
Years Considered for the Study2023-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD million/billion), Volume (thousand units)
SegmentsBy Product Type, Route Of Administration, Formulation Type, Indications, Animal Types, Distribution Channels, End User
Regions coveredNorth America, Europe, APAC, LATAM, MEA

Growth is supported by rising pet humanization, increasing prevalence of chronic and infectious diseases, and higher spending on advanced therapeutics. In livestock, productivity pressures and stricter food safety standards continue to drive pharmaceutical demand, sustaining consistent mid-single-digit market growth.

Veterinary Pharmaceuticals Market - IMG1

"By product type, the monoclonal antibodies segment is expected to witness the fastest growth rate during the forecast period."

The monoclonal antibodies segment is expected to grow fastest in the global veterinary pharmaceuticals market, supported by a growing preference for targeted and durable treatment options, especially in companion animals. The rising burden of chronic disorders, including atopic dermatitis, osteoarthritis, and immune-mediated conditions, is boosting demand. These therapies offer precise action, fewer adverse effects, and longer dosing intervals, improving compliance. Continued investment in biologics development and the expanding premium pet care market are further driving segment expansion.

"By indication, the dermatological diseases segment has accounted for the largest share in the Veterinary pharmaceuticals market in 2025."

The dermatological conditions segment is projected to hold the largest share of the global veterinary pharmaceuticals market in 2025, primarily due to the widespread occurrence of skin-related disorders in both companion and livestock animals. Common conditions such as atopic dermatitis, parasitic infections, fungal diseases, and bacterial skin infections require ongoing management and medication. Growing pet adoption, heightened focus on animal hygiene, and strong demand for anti-parasitic, antifungal, and anti-inflammatory treatments continue to reinforce the segment's dominant position.

"North America dominated the global veterinary pharmaceuticals market in 2025."

North America leads the veterinary pharmaceuticals market in 2025, supported by a mature animal healthcare ecosystem and strong purchasing power. The region records high spending on companion animal treatments and maintains a large commercial livestock base. Robust R&D investments, rapid approval pathways for innovative drugs, and the strong presence of established manufacturers further strengthen its position. Well-developed distribution networks and growing awareness of preventive animal care also contribute to its leading market position.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 - 45%, Tier 2 - 20%, and Tier 3 - 35%
  • By Designation: C-level - 35%, Director-level - 25%, and Others - 40%
  • By Region: North America - 40%, Europe - 25%, APAC - 20%, Latin America - 10%, Middle East & Africa - 5%

Research Coverage

This report examines the veterinary pharmaceuticals market by product type, route of administration, formulation type, indications, animal type, distribution channel, end user, and region. It also examines factors (such as drivers, restraints, opportunities, and challenges) that affect market growth. It analyzes market opportunities and challenges and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts market segment revenue across five main regions and their respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms gauge the market pulse, which, in turn, would help them gain a greater share. Firms purchasing the report could use one or a combination of the following five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the veterinary pharmaceuticals market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary pharmaceuticals market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of catheterization procedures across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary pharmaceuticals market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary pharmaceuticals market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN VETERINARY PHARMACEUTICALS MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY PHARMACEUTICALS MARKET
  • 3.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE AND COUNTRY
  • 3.3 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 3.4 VETERINARY PHARMACEUTICALS MARKET: DEVELOPING VS. DEVELOPED ECONOMIES, 2026-2031

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Rising companion animal ownership and pet humanization
      • 4.2.1.2 Growing prevalence of infectious and dermatological diseases in animals
      • 4.2.1.3 Increasing demand for animal-derived food products
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Growing concerns over antimicrobial resistance (AMR)
      • 4.2.2.2 Stringent regulatory approval processes for veterinary drugs
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Rising demand for parasiticides and dermatology products
      • 4.2.3.2 Growth potential in rural and low-income regions
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Monitoring drug residues in food-producing animals
      • 4.2.4.2 Balancing animal welfare, productivity, and compliance requirements
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMICS INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
    • 5.2.3 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY
    • 5.2.4 TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 SUPPLY CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023-2025
    • 5.6.2 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023-2025
    • 5.6.3 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023-2025
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT DATA FOR HS CODE 30, 2021-2024
      • 5.7.1.1 Import scenario (HS code 30)
    • 5.7.2 EXPORT DATA FOR HS CODE 30, 2021-2024
    • 5.7.3 EXPORT SCENARIO (HS CODE 30)
  • 5.8 KEY CONFERENCES AND EVENTS IN 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.10 INVESTMENT AND FUNDING SCENARIO
  • 5.11 CASE STUDY ANALYSIS
    • 5.11.1 ZOETIS INC.
    • 5.11.2 BOEHRINGER INGELHEIM ANIMAL HEALTH
    • 5.11.3 MERCK ANIMAL HEALTH
    • 5.11.4 ELANCO ANIMAL HEALTH
    • 5.11.5 CEVA SANTE ANIMALE
  • 5.12 IMPACT OF 2025 US TARIFF - VETERINARY PHARMACEUTICALS MARKET
    • 5.12.1 INTRODUCTION
    • 5.12.2 KEY TARIFF RATES
    • 5.12.3 PRICE IMPACT ANALYSIS
    • 5.12.4 IMPACT ON REGIONS
      • 5.12.4.1 North America
      • 5.12.4.2 Europe
      • 5.12.4.3 Asia Pacific
    • 5.12.5 IMPACT ON END-USE INDUSTRIES
      • 5.12.5.1 Veterinary hospitals & clinics
      • 5.12.5.2 Home care settings
      • 5.12.5.3 Livestock farms
      • 5.12.5.4 Rescue centers & NGOs
      • 5.12.5.5 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY EMERGING TECHNOLOGIES
      • 6.1.1.1 Controlled release formulation
      • 6.1.1.2 Biologics and monoclonal antibodies
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Digital health and telemedicine platforms
      • 6.1.2.2 Veterinary biomarker analysis
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Wearable animal health monitoring devices
      • 6.1.3.2 Stem cell therapy and regenerative medicine
  • 6.2 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3 PATENT ANALYSIS
    • 6.3.1 PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS
    • 6.3.2 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015-DECEMBER 2025
    • 6.3.3 LIST OF MAJOR PATENTS, 2023-2025
  • 6.4 FUTURE APPLICATIONS
    • 6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT
    • 6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT
    • 6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK
    • 6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL
  • 6.5 IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY FRAMEWORK
      • 7.1.1.1 North America
      • 7.1.1.2 Europe
    • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.3 INDUSTRY STANDARDS
      • 7.1.3.1 VICH Guidelines (International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products)
      • 7.1.3.2 Good Manufacturing Practice (GMP) Standards - PIC/S Guide (PE 009 series)
      • 7.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 - Maximum Residue Limits)
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET
      • 7.2.1.1 Virbac - Eco-pack to reduce single-use plastic in veterinary products
      • 7.2.1.2 Boehringer Ingelheim Animal Health - Renewable energy-powered manufacturing
      • 7.2.1.3 Boehringer Ingelheim - Recyclable veterinary delivery device (Aservo, EquiHaler)
  • 7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 PRODUCT INNOVATION AND DIFFERENTIATION
    • 8.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING
    • 8.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY

9 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE

  • 9.1 INTRODUCTION
    • 9.1.1 VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 9.2 DRUGS
    • 9.2.1 ANTI-BACTERIAL DRUGS
      • 9.2.1.1 Routine use in livestock and companion animals underpins strong market share and steady growth
    • 9.2.2 ANTI-FUNGAL DRUGS
      • 9.2.2.1 Limited approvals and off-label systemic use result in smaller but clinically essential segment
    • 9.2.3 ANTI-VIRAL DRUGS
      • 9.2.3.1 Low current penetration but rising research interest driven by outbreak response and targeted therapies
    • 9.2.4 ANTI-INFLAMMATORY DRUGS
      • 9.2.4.1 Rising surgical volumes and chronic pain management drive stable double-digit market share
    • 9.2.5 ANTI-PARASITIC DRUGS
      • 9.2.5.1 High parasitic burden and preventive care practices sustain market share and strong growth trajectory
    • 9.2.6 ANTI-CANCER DRUGS
      • 9.2.6.1 Increasing pet oncology awareness and advanced therapeutics to fuel growth from small base
    • 9.2.7 CARDIOVASCULAR AND RENAL DRUGS
      • 9.2.7.1 Rising diagnosis of chronic heart and kidney disorders supports steady mid-single-digit market share
    • 9.2.8 GASTROINTESTINAL DRUGS
      • 9.2.8.1 High incidence of digestive disorders and dietary transitions drive sustained demand
    • 9.2.9 OTHER DRUGS
  • 9.3 MONOCLONAL ANTIBODIES
    • 9.3.1 TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND
  • 9.4 IMMUNOMODULATORS
    • 9.4.1 INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE
  • 9.5 MEDICATED FEED ADDITIVES
    • 9.5.1 AMINO ACIDS
      • 9.5.1.1 Protein optimization and feed cost efficiency to drive demand
    • 9.5.2 ENZYMES
      • 9.5.2.1 Improved nutrient digestibility and cost optimization to support steady adoption
    • 9.5.3 VITAMINS AND MINERALS
      • 9.5.3.1 Essential micronutrient supplementation ensures largest market share
    • 9.5.4 OTHER MEDICATED FEED ADDITIVES

10 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION

  • 10.1 INTRODUCTION
  • 10.2 ORAL
    • 10.2.1 EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS
  • 10.3 PARENTERAL
    • 10.3.1 RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN CRITICAL CARE AND PRODUCTION SETTINGS
  • 10.4 TOPICAL
    • 10.4.1 RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED, NON-INVASIVE TREATMENTS
  • 10.5 OTHER ROUTES OF ADMINISTRATION

11 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE

  • 11.1 INTRODUCTION
  • 11.2 SOLID
    • 11.2.1 DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS
  • 11.3 LIQUID
    • 11.3.1 RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS
  • 11.4 SEMI-SOLID
    • 11.4.1 RISING DERMATOLOGY CASES AND INCREASING COMPANION ANIMAL CARE EXPENDITURE
  • 11.5 AEROSOL/SPRAY
    • 11.5.1 CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK
  • 11.6 PREMIX FORMULATIONS
    • 11.6.1 DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET

12 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION

  • 12.1 INTRODUCTION
  • 12.2 INFECTIOUS DISEASES
    • 12.2.1 ZOONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET
  • 12.3 DERMATOLOGICAL DISEASES
    • 12.3.1 RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET
  • 12.4 PAIN MANAGEMENT
    • 12.4.1 RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET
  • 12.5 CARDIOVASCULAR AND RENAL DISEASES
    • 12.5.1 INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET
  • 12.6 GASTROINTESTINAL DISEASES
    • 12.6.1 HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET
  • 12.7 OTHER INDICATIONS

13 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE

  • 13.1 INTRODUCTION
  • 13.2 COMPANION ANIMALS
    • 13.2.1 DOGS
      • 13.2.1.1 Increasing population and adoption of dogs to drive market
    • 13.2.2 CATS
      • 13.2.2.1 Emerging trends in feline pharmaceuticals to boost market
    • 13.2.3 HORSES
      • 13.2.3.1 Higher risk of traumatic injuries in horses to drive demand for veterinary pharmaceutical products
    • 13.2.4 OTHER COMPANION ANIMALS
  • 13.3 LIVESTOCK ANIMALS
    • 13.3.1 CATTLE
      • 13.3.1.1 Economic importance of dairy and beef cattle to drive growth
    • 13.3.2 SWINE
      • 13.3.2.1 Growing surgical volume for acute conditions in swine to drive market
    • 13.3.3 POULTRY
      • 13.3.3.1 Growing focus on infection prevention and flock health management to drive market
    • 13.3.4 OTHER LIVESTOCK ANIMALS

14 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 INTRODUCTION
  • 14.2 VETERINARY HOSPITAL PHARMACIES
    • 14.2.1 HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET
  • 14.3 RETAIL PHARMACIES
    • 14.3.1 RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS
  • 14.4 ONLINE PHARMACIES
    • 14.4.1 CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH
  • 14.5 DIRECT SALES
    • 14.5.1 DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS

15 VETERINARY PHARMACEUTICALS MARKET, BY END USER

  • 15.1 INTRODUCTION
  • 15.2 VETERINARY HOSPITALS & CLINICS
    • 15.2.1 FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS
  • 15.3 LIVESTOCK FARMS
    • 15.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE
  • 15.4 HOME CARE SETTINGS
    • 15.4.1 RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH
  • 15.5 OTHER END USERS

16 VETERINARY PHARMACEUTICALS MARKET, BY REGION

  • 16.1 INTRODUCTION
  • 16.2 NORTH AMERICA
    • 16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 16.2.2 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
    • 16.2.3 US
      • 16.2.3.1 Surge in animal healthcare expenditure to boost market
    • 16.2.4 CANADA
      • 16.2.4.1 Growing pet population and advanced veterinary services to drive market
  • 16.3 EUROPE
    • 16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 16.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
    • 16.3.3 GERMANY
      • 16.3.3.1 Increased focus on animal welfare to drive demand for veterinary pharmaceutical products
    • 16.3.4 UK
      • 16.3.4.1 Increasing pet ownership to propel market
    • 16.3.5 FRANCE
      • 16.3.5.1 High standards of veterinary care to provide attractive growth opportunities for market players
    • 16.3.6 ITALY
      • 16.3.6.1 Growing pet owner awareness and increasing livestock population to drive market
    • 16.3.7 SPAIN
      • 16.3.7.1 Increasing awareness of animal health to drive market
    • 16.3.8 REST OF EUROPE
  • 16.4 ASIA PACIFIC
    • 16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 16.4.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
    • 16.4.3 JAPAN
      • 16.4.3.1 Surge in pet care expenditure and growing adoption of companion animals to drive market
    • 16.4.4 CHINA
      • 16.4.4.1 Increasing animal healthcare expenditure and advancements in veterinary medicines to drive market
    • 16.4.5 INDIA
      • 16.4.5.1 Increasing livestock population to propel market growth
    • 16.4.6 AUSTRALIA
      • 16.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth
    • 16.4.7 SOUTH KOREA
      • 16.4.7.1 Growing pet ownership and advancements in veterinary medicine to favor market growth
    • 16.4.8 PHILIPPINES
      • 16.4.8.1 Tourism-linked pet culture and veterinary advancements to fuel market
    • 16.4.9 REST OF ASIA PACIFIC
  • 16.5 LATIN AMERICA
    • 16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 16.5.2 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
    • 16.5.3 BRAZIL
      • 16.5.3.1 Growing pet population and rising disposable incomes to drive market
    • 16.5.4 MEXICO
      • 16.5.4.1 Robust livestock base and growing companion animal care to drive market
    • 16.5.5 REST OF LATIN AMERICA
  • 16.6 MIDDLE EAST & AFRICA
    • 16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 16.6.2 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 16.7 GCC COUNTRIES
    • 16.7.1 KINGDOM OF SAUDI ARABIA (KSA)
      • 16.7.1.1 Vision 2030 investments to drive market
    • 16.7.2 UNITED ARAB EMIRATES (UAE)
      • 16.7.2.1 Increasing adoption of advanced diagnostic technologies to contribute to market growth
    • 16.7.3 REST OF GCC COUNTRIES
    • 16.7.4 REST OF MIDDLE EAST & AFRICA

17 COMPETITIVE LANDSCAPE

  • 17.1 INTRODUCTION
    • 17.1.1 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023-2026
  • 17.2 REVENUE ANALYSIS, 2023-2025
  • 17.3 MARKET SHARE ANALYSIS, 2025
    • 17.3.1 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
    • 17.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
  • 17.4 PRODUCT/BRAND COMPARISON
  • 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 17.5.1 STARS
    • 17.5.2 EMERGING LEADERS
    • 17.5.3 PERVASIVE PLAYERS
    • 17.5.4 PARTICIPANTS
    • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 17.5.5.1 Company footprint
      • 17.5.5.2 Region footprint
      • 17.5.5.3 Product type footprint
      • 17.5.5.4 Route of administration footprint
      • 17.5.5.5 Indication footprint
      • 17.5.5.6 End user footprint
  • 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 17.6.1 PROGRESSIVE COMPANIES
    • 17.6.2 RESPONSIVE COMPANIES
    • 17.6.3 DYNAMIC COMPANIES
    • 17.6.4 STARTING BLOCKS
    • 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 17.6.5.1 Detailed list of key startups/SMEs
      • 17.6.5.2 Competitive benchmarking of key startups/SMEs
  • 17.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 17.8 COMPETITIVE SCENARIO
    • 17.8.1 PRODUCT LAUNCHES & APPROVALS
    • 17.8.2 DEALS
    • 17.8.3 EXPANSIONS
    • 17.8.4 OTHER DEVELOPMENTS

18 COMPANY PROFILES

  • 18.1 KEY PLAYERS
    • 18.1.1 ZOETIS INC.
      • 18.1.1.1 Business overview
      • 18.1.1.2 Products offered
      • 18.1.1.3 Recent developments
        • 18.1.1.3.1 Product launches & approvals
        • 18.1.1.3.2 Expansions
        • 18.1.1.3.3 Other developments
      • 18.1.1.4 MnM view
        • 18.1.1.4.1 Right to win
        • 18.1.1.4.2 Strategic choices
        • 18.1.1.4.3 Weaknesses and competitive threats
    • 18.1.2 MERCK & CO., INC
      • 18.1.2.1 Business overview
      • 18.1.2.2 Products offered
      • 18.1.2.3 Recent developments
        • 18.1.2.3.1 Product launches & approvals
        • 18.1.2.3.2 Deals
        • 18.1.2.3.3 Expansions
      • 18.1.2.4 MnM view
        • 18.1.2.4.1 Right to win
        • 18.1.2.4.2 Strategic choices
        • 18.1.2.4.3 Weaknesses and competitive threats
    • 18.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 18.1.3.1 Business overview
      • 18.1.3.2 Products offered
      • 18.1.3.3 Recent developments
        • 18.1.3.3.1 Product launches & approvals
        • 18.1.3.3.2 Deals
        • 18.1.3.3.3 Expansions
      • 18.1.3.4 MnM view
        • 18.1.3.4.1 Right to win
        • 18.1.3.4.2 Strategic choices
        • 18.1.3.4.3 Weaknesses and competitive threats
    • 18.1.4 ELANCO ANIMAL HEALTH INCORPORATED
      • 18.1.4.1 Business overview
      • 18.1.4.2 Products offered
      • 18.1.4.3 Recent developments
        • 18.1.4.3.1 Product launches & approvals
        • 18.1.4.3.2 Expansions
        • 18.1.4.3.3 Other developments
      • 18.1.4.4 MnM view
        • 18.1.4.4.1 Right to win
        • 18.1.4.4.2 Strategic choices
        • 18.1.4.4.3 Weaknesses and competitive threats
    • 18.1.5 VIRBAC
      • 18.1.5.1 Business overview
      • 18.1.5.2 Products offered
      • 18.1.5.3 Recent developments
        • 18.1.5.3.1 Product launches & approvals
        • 18.1.5.3.2 Deal
        • 18.1.5.3.3 Expansions
      • 18.1.5.4 MnM view
        • 18.1.5.4.1 Right to win
        • 18.1.5.4.2 Strategic choices
        • 18.1.5.4.3 Weaknesses and competitive threats
    • 18.1.6 CEVA
      • 18.1.6.1 Business overview
      • 18.1.6.2 Products offered
      • 18.1.6.3 Recent developments
        • 18.1.6.3.1 Deals
        • 18.1.6.3.2 Expansions
    • 18.1.7 VETOQUINOL
      • 18.1.7.1 Business overview
      • 18.1.7.2 Products offered
      • 18.1.7.3 Recent developments
        • 18.1.7.3.1 Product launches & approvals
        • 18.1.7.3.2 Deals
    • 18.1.8 DECHRA PHARMACEUTICALS PLC
      • 18.1.8.1 Business overview
      • 18.1.8.2 Products offered
      • 18.1.8.3 Recent developments
        • 18.1.8.3.1 Product launches & approvals
        • 18.1.8.3.2 Deals
        • 18.1.8.3.3 Other developments
    • 18.1.9 NORBROOK
      • 18.1.9.1 Business overview
      • 18.1.9.2 Products offered
      • 18.1.9.3 Recent developments
        • 18.1.9.3.1 Product launches & approvals
        • 18.1.9.3.2 Deals
        • 18.1.9.3.3 Expansions
        • 18.1.9.3.4 Other developments
    • 18.1.10 BIMEDA CORPORATE
      • 18.1.10.1 Business overview
      • 18.1.10.2 Products offered
      • 18.1.10.3 Recent developments
        • 18.1.10.3.1 Product launches & approvals
        • 18.1.10.3.2 Deals
        • 18.1.10.3.3 Expansions
    • 18.1.11 HESTER BIOSCIENCES LIMITED
      • 18.1.11.1 Business overview
      • 18.1.11.2 Products offered
    • 18.1.12 INDIAN IMMUNOLOGICALS LTD.
      • 18.1.12.1 Business overview
      • 18.1.12.2 Products offered
    • 18.1.13 ANIMALCARE GROUP PLC
      • 18.1.13.1 Business overview
      • 18.1.13.2 Products offered
      • 18.1.13.3 Recent developments
        • 18.1.13.3.1 Deals
        • 18.1.13.3.2 Product launches & approvals
    • 18.1.14 KYORITSU SEIYAKU CORPORATION
      • 18.1.14.1 Business overview
      • 18.1.14.2 Products offered
      • 18.1.14.3 Recent developments
        • 18.1.14.3.1 Product launches & approvals
        • 18.1.14.3.2 Deals
    • 18.1.15 CALIER
      • 18.1.15.1 Business overview
      • 18.1.15.2 Products offered
      • 18.1.15.3 Recent developments
        • 18.1.15.3.1 Product launches & approvals
  • 18.2 OTHER PLAYERS
    • 18.2.1 DOPHARMA
    • 18.2.2 PHARMGATE ANIMAL HEALTH
    • 18.2.3 BIOVETA, A.S.
    • 18.2.4 NEXTMUNE
    • 18.2.5 TRIVIUMVET
    • 18.2.6 DOMES PHARMA
    • 18.2.7 UNIVET LIMITED
    • 18.2.8 CENAVISA, S.L.
    • 18.2.9 FATRO S.P.A.
    • 18.2.10 CHANELLE PHARMA

19 RESEARCH METHODOLOGY

  • 19.1 RESEARCH DATA
    • 19.1.1 SECONDARY DATA
      • 19.1.1.1 Key data from secondary sources
    • 19.1.2 PRIMARY DATA
      • 19.1.2.1 Key data from primary sources
      • 19.1.2.2 Key industry insights
      • 19.1.2.3 Key industry insights
  • 19.2 MARKET SIZE ESTIMATION
  • 19.3 GROWTH FORECAST
    • 19.3.1 KEY INDUSTRY INSIGHTS
  • 19.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 19.5 RESEARCH ASSUMPTIONS
  • 19.6 RESEARCH LIMITATIONS
  • 19.7 RISK ASSESSMENT

20 APPENDIX

  • 20.1 DISCUSSION GUIDE
  • 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 20.3 CUSTOMIZATION OPTIONS
    • 20.3.1 PRODUCT ANALYSIS
    • 20.3.2 US END USER ANALYSIS
    • 20.3.3 GEOGRAPHIC ANALYSIS
    • 20.3.4 COMPANY INFORMATION
    • 20.3.5 REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS
    • 20.3.6 COUNTRY LEVEL VOLUME ANALYSIS BY PRODUCT TYPE
    • 20.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
    • 20.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
  • 20.4 RELATED REPORTS
  • 20.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
  • TABLE 2 PET (DOGS AND CATS) OWNERSHIP STATISTICS IN US, 2024
  • TABLE 3 COMPANION ANIMAL POPULATION STATISTICS, BY REGION
  • TABLE 4 RECENT GOVERNMENT-REPORTED INDICATORS
  • TABLE 5 TRENDS IN CONSUMPTION OF MEAT & MILK IN DEVELOPED & EMERGING ECONOMIES
  • TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 8 UNMET CUSTOMER NEEDS AND WHITE SPACES IN VETERINARY PHARMACEUTICALS MARKET.
  • TABLE 9 INTERCONNECTED MARKETS IN VETERINARY PHARMACEUTICALS MARKET
  • TABLE 10 CROSS-SECTOR MARKETS IN VETERINARY PHARMACEUTICALS MARKET
  • TABLE 11 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • TABLE 12 IMPACT OF PORTER'S FIVE FORCES ON VETERINARY PHARMACEUTICALS MARKET
  • TABLE 13 GDP TREND AND FORECAST, BY COUNTRY, 2021-2030 (USD BILLION)
  • TABLE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023-2025
  • TABLE 15 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023-2025
  • TABLE 16 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023-2025
  • TABLE 17 IMPORT DATA FOR HS CODE 30, BY COUNTRY, 2021-2024 (USD MILLION)
  • TABLE 18 EXPORT DATA FOR HS CODE 30, BY COUNTRY, 2021-2024 (USD MILLION)
  • TABLE 19 DETAILED LIST OF CONFERENCES AND EVENTS, 2026-2027
  • TABLE 20 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 21 TECHNOLOGY/PRODUCT ROADMAP
  • TABLE 22 VETERINARY PHARMACEUTICALS MARKET: LIST OF MAJOR PATENTS, JANUARY 2023-DECEMBER 2025
  • TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS
  • TABLE 28 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 29 VETERINARY PHARMACEUTICALS MARKET: UNMET NEEDS IN KEY END-USE SETTINGS
  • TABLE 30 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • TABLE 31 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 32 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 33 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 34 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-BACTERIAL DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 35 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-FUNGAL DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 36 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-VIRAL DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 37 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 38 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-PARASITIC DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 39 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-CANCER DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 40 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 41 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 42 VETERINARY PHARMACEUTICALS MARKET FOR OTHER DRUGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 43 VETERINARY PHARMACEUTICALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 44 VETERINARY PHARMACEUTICALS MARKET FOR IMMUNOMODULATORS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 45 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 46 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 47 VETERINARY PHARMACEUTICALS MARKET FOR AMINO ACIDS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 48 VETERINARY PHARMACEUTICALS MARKET FOR ENZYMES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 49 VETERINARY PHARMACEUTICALS MARKET FOR VITAMINS AND MINERALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 50 VETERINARY PHARMACEUTICALS MARKET FOR OTHER MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 51 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 52 VETERINARY PHARMACEUTICALS MARKET FOR ORAL, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 53 VETERINARY PHARMACEUTICALS MARKET FOR PARENTERAL, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 54 VETERINARY PHARMACEUTICALS MARKET FOR TOPICAL, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 55 VETERINARY PHARMACEUTICALS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 56 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 57 VETERINARY PHARMACEUTICALS MARKET FOR SOLID, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 58 VETERINARY PHARMACEUTICALS MARKET FOR LIQUID, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 59 VETERINARY PHARMACEUTICALS MARKET FOR SEMI-SOLID, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 60 VETERINARY PHARMACEUTICALS MARKET FOR AEROSOL/SPRAY, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 61 VETERINARY PHARMACEUTICALS MARKET FOR PREMIX FORMULATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 62 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 63 VETERINARY PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 64 VETERINARY PHARMACEUTICALS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 65 VETERINARY PHARMACEUTICALS MARKET FOR PAIN MANAGEMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 66 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DISEASES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 67 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 68 VETERINARY PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 69 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 70 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 71 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 72 VETERINARY PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 73 VETERINARY PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 74 VETERINARY PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 75 VETERINARY PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 76 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 77 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 78 VETERINARY PHARMACEUTICALS MARKET FOR CATTLE, BY COUNTRY/ REGION, 2024-2031 (USD MILLION)
  • TABLE 79 VETERINARY PHARMACEUTICALS MARKET FOR SWINE, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 80 VETERINARY PHARMACEUTICALS MARKET FOR POULTRY, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 81 VETERINARY PHARMACEUTICALS MARKET FOR OTHER LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 82 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 83 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITAL PHARMACIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 84 VETERINARY PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 85 VETERINARY PHARMACEUTICALS MARKET FOR ONLINE PHARMACIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 86 VETERINARY PHARMACEUTICALS MARKET FOR DIRECT SALES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 87 VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 88 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 89 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK FARMS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 90 VETERINARY PHARMACEUTICALS MARKET FOR HOME CARE SETTINGS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 91 VETERINARY PHARMACEUTICALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 VETERINARY PHARMACEUTICALS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 93 VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 96 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • TABLE 97 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 98 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 100 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 101 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 102 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 103 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 104 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 105 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 106 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 107 US: KEY MACRO INDICATORS
  • TABLE 108 US: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 109 US: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 110 US: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 111 US: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 112 US: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 113 US: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 114 US: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 115 US: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 116 US: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 US: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 118 US: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 119 CANADA: KEY MACRO INDICATORS
  • TABLE 120 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 121 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 123 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 124 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 125 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 126 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 129 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 130 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 131 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • TABLE 134 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 135 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 136 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 137 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 138 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 139 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 141 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 142 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 143 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 144 GERMANY: KEY MACRO INDICATORS
  • TABLE 145 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 146 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 147 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 148 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 149 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 150 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 151 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 152 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 153 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 154 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 155 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 156 UK: KEY MACRO INDICATORS
  • TABLE 157 UK: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 158 UK: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 159 UK: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 160 UK: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 161 UK: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 162 UK: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 163 UK: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 164 UK: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 165 UK: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 166 UK: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 167 UK: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 168 FRANCE: KEY MACRO INDICATORS
  • TABLE 169 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 171 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 172 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 173 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 174 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 175 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 176 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 178 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 179 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 180 ITALY: KEY MACRO INDICATORS
  • TABLE 181 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 182 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 183 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 184 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 185 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 186 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 187 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 188 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 189 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 190 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 191 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 192 SPAIN: KEY MACRO INDICATORS
  • TABLE 193 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 194 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 195 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 196 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 197 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 198 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 199 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 200 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 201 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 202 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 203 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 204 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 205 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 207 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 208 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 209 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 210 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 211 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 212 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 213 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 214 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • TABLE 218 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 228 JAPAN: KEY MACRO INDICATORS
  • TABLE 229 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 230 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 232 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
  • TABLE 233 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024-2031 (USD MILLION)
  • TABLE 234 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 235 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024-2031 (USD MILLION)
  • TABLE 236 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 237 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 238 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 239 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: MEDICAL FURNITURE MARKET, VOLUME DATA, 2024-2031 (THOUSAND UNITS)
  • TABLE 221 ASIA PACIFIC: MEDICAL FURNITURE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 234 CHINA: KEY MACROINDICATORS
  • TABLE 235 CHINA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 236 CHINA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 237 CHINA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 238 CHINA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATINGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 239 CHINA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 240 CHINA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 241 CHINA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 242 CHINA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 CHINA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 244 CHINA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 245 CHINA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 246 CHINA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 247 JAPAN: KEY MACROINDICATORS
  • TABLE 248 JAPAN: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 249 JAPAN: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 250 JAPAN: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 251 JAPAN: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATINGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 JAPAN: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 253 JAPAN: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 254 JAPAN: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 255 JAPAN: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 256 JAPAN: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 257 JAPAN: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 258 JAPAN: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 259 JAPAN: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 260 INDIA: KEY MACROINDICATORS
  • TABLE 261 INDIA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 262 INDIA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 263 INDIA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 264 INDIA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATINGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 265 INDIA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 266 INDIA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 267 INDIA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 268 INDIA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 INDIA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 INDIA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 271 INDIA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 272 INDIA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 274 AUSTRALIA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 275 AUSTRALIA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 276 AUSTRALIA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 AUSTRALIA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATINGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 278 AUSTRALIA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 279 AUSTRALIA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 280 AUSTRALIA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 281 AUSTRALIA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 282 AUSTRALIA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 283 AUSTRALIA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 284 AUSTRALIA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 285 AUSTRALIA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 287 SOUTH KOREA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 288 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 289 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 290 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATINGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 291 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 292 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 294 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 295 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 296 SOUTH KOREA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 297 SOUTH KOREA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 298 SOUTH KOREA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 299 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 300 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 301 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 302 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATINGS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 303 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 305 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 307 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 308 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 309 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 310 REST OF ASIA PACIFIC: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 311 LATIN AMERICA: MEDICAL FURNITURE MARKET, VOLUME DATA, 2024-2031 (THOUSAND UNITS)
  • TABLE 312 LATIN AMERICA: MEDICAL FURNITURE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 313 LATIN AMERICA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 314 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 315 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 316 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 317 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 318 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 319 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 320 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 321 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 322 LATIN AMERICA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 323 LATIN AMERICA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 324 LATIN AMERICA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 BRAZIL: KEY MACROINDICATORS
  • TABLE 326 BRAZIL: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 327 BRAZIL: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 328 BRAZIL: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 329 BRAZIL: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 330 BRAZIL: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 331 BRAZIL: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 332 BRAZIL: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 333 BRAZIL: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 334 BRAZIL: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 335 BRAZIL: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 336 BRAZIL: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 337 BRAZIL: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 338 MEXICO: KEY MACROINDICATORS
  • TABLE 339 MEXICO: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 340 MEXICO: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 341 MEXICO: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 342 MEXICO: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 343 MEXICO: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 MEXICO: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 345 MEXICO: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 346 MEXICO: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 347 MEXICO: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 MEXICO: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 349 MEXICO: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 350 MEXICO: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 351 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 352 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 353 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 354 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 355 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 356 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 357 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 358 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 359 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 360 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 361 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 362 REST OF LATIN AMERICA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 363 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, VOLUME DATA, 2024-2031 (THOUSAND UNITS)
  • TABLE 364 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 365 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 366 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 367 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 368 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 369 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 370 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 371 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 372 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 373 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 374 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 375 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 376 MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 377 GCC COUNTRIES: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 378 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 379 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 380 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 381 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 382 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 383 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 384 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 385 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 386 GCC COUNTRIES: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 387 GCC COUNTRIES: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 388 GCC COUNTRIES: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 389 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 390 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 391 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR MEDICAL BEDS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 392 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR CHAIRS & SEATING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 393 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR TABLES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 394 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR STRETCHERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 395 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR CABINETS, LOCKERS, AND STORAGE UNITS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 396 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR TROLLEYS & CARTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 397 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 398 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 399 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 400 REST OF MIDDLE EAST & AFRICA: MEDICAL FURNITURE MARKET FOR HOSPITALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 401 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN MEDICAL FURNITURE MARKET
  • TABLE 402 MEDICAL FURNITURE MARKET: DEGREE OF COMPETITION
  • TABLE 403 MEDICAL FURNITURE MARKET: REGION FOOTPRINT
  • TABLE 404 MEDICAL FURNITURE MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 405 MEDICAL FURNITURE MARKET: APPLICATION FOOTPRINT
  • TABLE 406 MEDICAL FURNITURE MARKET: END USER FOOTPRINT
  • TABLE 407 MEDICAL FURNITURE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 408 MEDICAL FURNITURE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 409 MEDICAL FURNITURE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 410 MEDICAL FURNITURE MARKET: DEALS, JANUARY 2022-JANUARY 2026
  • TABLE 411 MEDICAL FURNITURE MARKET: EXPANSIONS, JANUARY 2022-JANUARY 2026
  • TABLE 412 MEDICAL FURNITURE MARKET: OTHER DEVELOPMENTS, JANUARY 2022-JANUARY 2026
  • TABLE 413 ARJO: COMPANY OVERVIEW
  • TABLE 414 ARJO: PRODUCTS OFFERED
  • TABLE 415 ARJO: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 416 ARJO: OTHER DEVELOPMENTS, JANUARY 2022-JANUARY 2026
  • TABLE 417 GETINGE AB: COMPANY OVERVIEW
  • TABLE 418 GETINGE AB: PRODUCTS OFFERED
  • TABLE 419 GETINGE AB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 420 GETINGE AB: DEALS, JANUARY 2022- JANUARY 2026
  • TABLE 421 GETINGE AB: EXPANSIONS, JANUARY 2022- JANUARY 2026
  • TABLE 422 BAXTER: COMPANY OVERVIEW
  • TABLE 423 BAXTER: PRODUCTS OFFERED
  • TABLE 424 BAXTER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 425 STRYKER: COMPANY OVERVIEW
  • TABLE 426 STRYKER: PRODUCTS OFFERED
  • TABLE 427 STRYKER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 428 PARAMOUNT BED HOLDINGS CO., LTD.: COMPANY OVERVIEW
  • TABLE 429 PARAMOUNT BED HOLDINGS CO., LTD.: PRODUCTS OFFERED
  • TABLE 430 PARAMOUNT BED HOLDINGS CO., LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 431 STERIS: COMPANY OVERVIEW
  • TABLE 432 STERIS: PRODUCTS OFFERED
  • TABLE 433 MILLERKNOLL, INC.: COMPANY OVERVIEW
  • TABLE 434 MILLERKNOLL, INC.: PRODUCTS OFFERED
  • TABLE 435 MILLERKNOLL, INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 436 SAVARIA: COMPANY OVERVIEW
  • TABLE 437 SAVARIA: PRODUCTS OFFERED
  • TABLE 438 LINET: COMPANY OVERVIEW
  • TABLE 439 LINET: PRODUCTS OFFERED
  • TABLE 440 LINET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 441 LINET: DEALS, JANUARY 2022- JANUARY 2026
  • TABLE 442 LINET: EXPANSIONS, JANUARY 2022-JANUARY 2026
  • TABLE 443 DRIVE DEVILBISS HEALTHCARE: COMPANY OVERVIEW
  • TABLE 444 DRIVE DEVILBISS HEALTHCARE: PRODUCTS OFFERED
  • TABLE 445 DRIVE DEVILBISS HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022-JANUARY 2026
  • TABLE 446 JOERNS HEALTHCARE: COMPANY OVERVIEW
  • TABLE 447 JOERNS HEALTHCARE: PRODUCTS OFFERED
  • TABLE 448 JOERNS HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JANUARY 2026
  • TABLE 449 STIEGELMEYER GMBH & CO. KG: COMPANY OVERVIEW
  • TABLE 450 STIEGELMEYER GMBH & CO. KG: PRODUCTS OFFERED
  • TABLE 451 MALVESTIO SPA: COMPANY OVERVIEW
  • TABLE 452 MALVESTIO SPA: PRODUCTS OFFERED
  • TABLE 453 NARANG MEDICAL LIMITED: COMPANY OVERVIEW
  • TABLE 454 GF HEALTH PRODUCTS, INC.: COMPANY OVERVIEW
  • TABLE 455 PROMOTAL: COMPANY OVERVIEW
  • TABLE 456 GPC MEDICAL LTD.: COMPANY OVERVIEW
  • TABLE 457 KOVONAX SPOL. S R.O.: COMPANY OVERVIEW
  • TABLE 458 SKYTRON LLC: COMPANY OVERVIEW
  • TABLE 459 MIDMARK CORPORATION: COMPANY OVERVIEW
  • TABLE 460 MEDIFA: COMPANY OVERVIEW
  • TABLE 461 MERIVAARA CORP.: COMPANY OVERVIEW
  • TABLE 462 AMICO GROUP OF COMPANIES.: COMPANY OVERVIEW
  • TABLE 463 UMANO MEDICAL INC.: COMPANY OVERVIEW
  • TABLE 464 OPERA BEDS: COMPANY OVERVIEW
  • TABLE 465 MEDICAL FURNITURE MARKET: STUDY ASSUMPTIONS
  • TABLE 466 MEDICAL FURNITURE MARKET: RISK ASSESSMENT ANALYSIS

List of Figures

  • FIGURE 1 VETERINARY PHARMACEUTICALS MARKET SEGMENTATION
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 VETERINARY PHARMACEUTICALS MARKET, 2024-2031
  • FIGURE 4 VETERINARY PHARMACEUTICALS MARKET: MAJOR STRATEGIES ADOPTED BY KEY PLAYERS, 2022-2025
  • FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY PHARMACEUTICALS MARKET
  • FIGURE 6 VETERINARY PHARMACEUTICALS MARKET: HIGH-GROWTH SEGMENTS, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 8 INCREASING PET CARE EXPENDITURE TO DRIVE MARKET
  • FIGURE 9 DRUGS SEGMENT AND CHINA DOMINATED MARKET IN 2025
  • FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 11 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 12 VETERINARY PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 PET POPULATION IN MAJOR MARKETS, 2022 (MILLION)
  • FIGURE 14 EUROPE: PET POPULATION, 2021-2023
  • FIGURE 15 VETERINARY PHARMACEUTICALS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 16 VETERINARY PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 17 VETERINARY PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 18 VETERINARY PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 19 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 20 INVESTMENT/VENTURE CAPITAL SCENARIO IN VETERINARY PHARMACEUTICALS MARKET, 2021-2025
  • FIGURE 21 PATENTS APPLIED AND GRANTED, JANUARY 2015-DECEMBER 2025
  • FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY PHARMACEUTICALS PRODUCTS, JANUARY 2015-DECEMBER 2025
  • FIGURE 23 VETERINARY PHARMACEUTICALS MARKET: DECISION-MAKING FACTORS
  • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS
  • FIGURE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • FIGURE 27 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 28 NORTH AMERICA: EXPECTED GROWTH IN NUMBER OF VETERINARIANS, 2020-2030
  • FIGURE 29 NORTH AMERICA: PET POPULATION, 2024 (MILLION)
  • FIGURE 30 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 31 US: TOTAL PET HEALTH EXPENDITURE, 2020-2024
  • FIGURE 32 EUROPE: PET POPULATION, 2023 (MILLION)
  • FIGURE 33 ASIA PACIFIC: DOG POPULATION, BY COUNTRY, 2024
  • FIGURE 34 ASIA PACIFIC: CAT POPULATION, BY COUNTRY, 2024
  • FIGURE 35 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 36 VETERINARY PHARMACEUTICALS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2023-2025
  • FIGURE 37 VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
  • FIGURE 38 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
  • FIGURE 39 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
  • FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 41 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 42 VETERINARY PHARMACEUTICALS MARKET: COMPANY FOOTPRINT
  • FIGURE 43 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 44 EV/EBITDA OF KEY VENDORS
  • FIGURE 45 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 46 ZOETIS INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 47 MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025)
  • FIGURE 49 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2025)
  • FIGURE 50 VIRBAC: COMPANY SNAPSHOT (2025)
  • FIGURE 51 CEVA: COMPANY SNAPSHOT (2025)
  • FIGURE 52 VETOQUINOL: COMPANY SNAPSHOT (2025)
  • FIGURE 53 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2025)
  • FIGURE 54 INDIAN IMMUNOLOGICALS LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 55 ANIMALCARE GROUP PLC: COMPANY SNAPSHOT
  • FIGURE 56 RESEARCH DESIGN
  • FIGURE 57 PRIMARY SOURCES
  • FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS
  • FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS
  • FIGURE 60 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 61 MARKET SIZE ESTIMATION APPROACH: REVENUE SHARE ANALYSIS
  • FIGURE 62 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025)
  • FIGURE 63 VETERINARY PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS
  • FIGURE 64 TOP-DOWN APPROACH
  • FIGURE 65 VETERINARY PHARMACEUTICALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026-2031)
  • FIGURE 66 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF VETERINARY PHARMACEUTICALS MARKET (2026-2031)
  • FIGURE 67 DATA TRIANGULATION